文献速递前列腺增生与排尿功能障碍前列腺癌

他汀类药物使用与前列腺体积纵向变化:REDUCE试验结果

Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
PubMed 文献 · BJU Int · 2019-09-27

基于REDUCE随机对照试验数据,纳入4106名基线前列腺活检阴性且未接受手术或发生前列腺癌的男性,评估他汀使用与前列腺体积变化的关系。结果显示他汀使用者前列腺体积随时间下降(P=0.027),在度他雄胺组2年和4年时体积分别低4.5%(P=0.032)和4.0%(P=0.033),安慰剂组有类似但非显著趋势。结论提示他汀可能适度减缓前列腺体积增长。

要点

  • 他汀使用者前列腺体积随时间呈下降趋势,总体P=0.027。
  • 度他雄胺组他汀使用者2年体积低4.5%,4年低4.0%,均显著。
  • 安慰剂组有类似3-3.3%效应但未达统计学显著。

核心结论

  • 他汀使用与前列腺体积随时间适度减缓增长相关,效应幅度约4%,与既往报道的他汀降低PSA效应一致。

研究设计与样本

  • REDUCE随机对照试验的事后分析,纳入4106名基线前列腺活检阴性且未接受前列腺手术或发生前列腺癌的男性。
  • 他汀使用在基线自我报告,前列腺体积通过经直肠超声在基线、2年和4年时测定。

主要发现

  • 4106名男性中17%在基线使用他汀,基线前列腺体积无差异。
  • 他汀使用者前列腺体积随时间下降(P=0.027),度他雄胺组2年体积低4.5%(P=0.032)、4年低4.0%(P=0.033)。
  • 安慰剂组有类似3-3.3%效应但无统计学显著性。

临床怎么用

  • 他汀可能适度减缓前列腺体积增长,但需未来研究确认是否影响下尿路症状的发生或进展。

局限性

  • 他汀使用为基线自我报告,可能受混杂因素影响;安慰剂组效应未达显著;需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test the association between statin use and prostate volume (PV) change over time using data from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial, a 4-year randomised controlled trial testing dutasteride for prostate cancer chemoprevention. SUBJECTS/PATIENTS AND METHODS: We identified men with a baseline negative prostate biopsy from REDUCE who did not undergo prostate surgery or develop prostate cancer over the trial period. Men reported statin use at baseline. PV was determined from transrectal ultrasonography performed to guide prostate biopsy at baseline, and 2- and 4-years after randomisation. Multivariable generalised estimating equations tested differences in PV change over time by statin use, overall and stratified by treatment arm. We tested for interactions between statins and time in association with PV using the Wald test. RESULTS: Of 4106 men, 17% used statins at baseline. Baseline PV did not differ by statin use. Relative to non-users, statin users had decreasing PVs over the trial period (P = 0.027). Similar patterns were seen in the dutasteride and placebo arms, although neither reached statistical significance. The mean estimated PV was modestly but significantly lower in statin users relative to non-users in the dutasteride arm at 2-years (4.5%, P = 0.032) and 4-years (4.0%, P = 0.033), with similar (3-3.3%) but non-significant effects in the placebo arm. CONCLUSION: If confirmed, our present findings support a role for statins in modestly attenuating PV growth, with a magnitude of effect in line with previously reported prostate-specific antigen-lowering effects of statins (~4%). Future studies are needed to assess whether this putative role for statins in PV growth could impact lower urinary tract symptom development or progression.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Allott EH, Csizmadi I, Howard LE, et al. Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. BJU Int. 2019. PMID: 31479563. doi:10.1111/bju.14905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。